Vir, GSK launch late-stage clinical trial of monoclonal antibody for Covid-19 virus
The companies said Monday that they had launched the Phase II/III COMET-ICE trial of VIR-7831, which will enroll about 1,300 patients around the world and investigate the drug as a way to prevent hospitalization of high-risk individuals infected with SARS-CoV-2.